Advertisement

Remdesivir Has ‘Little Or No Effect’ On COVID-19 Mortality: WHO Study

Channels Television  
Updated October 16, 2020
This file photo taken on April 8, 2020 shows one vial of the drug Remdesivir during a press conference about the start of a study with the Ebola drug Remdesivir in particularly severely ill patients at the University Hospital Eppendorf (UKE) in Hamburg, northern Germany, amidst the new coronavirus COVID-19 pandemic. Ulrich Perrey / POOL / AFP
This file photo taken on April 8, 2020 shows one vial of the drug Remdesivir during a press conference about the start of a study with the Ebola drug Remdesivir in particularly severely ill patients at the University Hospital Eppendorf (UKE) in Hamburg, northern Germany, amidst the new coronavirus COVID-19 pandemic. Ulrich Perrey / POOL / AFP

 

The antiviral drug remdesivir, considered one of the most promising COVID-19 treatments, turns out to do little to prevent deaths from the disease, according to a WHO-backed study.

Remdesivir, which was part of the experimental cocktail given to US President Donald Trump when he caught the new coronavirus last month, was one of several reviewed in a large study of more than 11,000 people across 30 countries.

The drug “appeared to have little or no effect on hospitalised COVID-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay,” said the study posted online late Thursday.

The data, which has yet to be peer-reviewed or published in a scientific journal, seems to contradict at least two major US studies that have shown that remdesivir can reduce the duration of hospital stays for COVID-19 patients.

Washington authorised the emergency use of the medicine, made by US pharmaceutical company Gilead Sciences and originally intended as a treatment for Ebola — on May 1, followed by a range of other countries and the European Union.

 

 

 

-AFP